MCQs on Clinical Management of COVID-19 in Adults & Management of Mucormycosis

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

Date of Test

YYYY

Name of the participant

Designation:

Posted at including block name

District

Contact No. *

Q 1. Incubation period for Corona virus Disease 2019 (Covid-19).

1 point

a) 1-5 Days

b) 5-7 Days

c) 7-14 days

d) 1-14 days

Clear selection

Q2. Symptoms of severe illness of COVID 19 patient

1 point

a) Fever, Cough or change in test or smell

b) Clinical or radiographic evidences of lower Respiratory tract disease, Oxygen saturation >94%

c) Oxygen saturation < 94%, Respiratory rate >30 breath/min, lung infiltrates >50%

d) Positive SARS-CoV-2 Test, No symptoms

Clear selection

Q3. Person associated with severe illness and higher mortality from COVID-19:-

1 point

a. Cancer, Cerebrovascular disease, Chronic kidney disease

b) Diabetes mellitus, type 1 and type 2,Down syndrome, Heart conditions (such as heart failure, coronary artery disease, or cardiomyopathies),HIV

c) Overweight and obesity (BMI ≥30 kg/m2),Pregnancy

d) Above all

Clear selection

Q 4. In Asia highest cases of Mucormycosis

1 point

a) India

b) Nepal

c) Pakistan

d) Bangladesh

Clear selection

Q 5. Various types of Mucormycosis

1 point

a) Rhino orbital cerebral

b) Pulmonary

c) Cutaneous

d) All of the above

Clear selection

Q6 . Probable reasons for increase in incidence of Mucormycosis in COVID 19 Patients

1 point

a) COVID 19 with DM

b) Steroid Therapy

c) Oxygen Humidifier

d) All above

Clear selection

Q7. When to Suspect Mucormycosis

1 point

a) Sinusitis – nasal blockade or congestion, nasal discharge (blackish/bloody),

b) One sided facial pain, numbness or swelling

c) Blackish discoloration over bridge of nose/palate

d) Blurred or double vision with pain; fever, skin lesion; thrombosis & necrosis (eschar)

e) All above

Clear selection

Q8. Symptoms of Mucormycosis

1 point

a) Pain in tooth or Jaw

b) Swelling on Face

c) Redness or swelling in eye

d) Fever

e) All above

Clear selection

Q9. Which is not a antifungal indicated for Mucormycosis

1 point

a) Amphotericin B

b) Posaconazole

c) Fluconazole

d) Isavuconazole

Clear selection

10. Diagnosis of Mucormycosis

1 point

a) Clinical Examination by symptoms

b) Histopathology and KOH staining

c) Contrast enhanced MRI

d) NCCTPNS

e) All the above

Clear selection

11 . Mortality percentage by Mucormycosis

1 point

a) 80%

b) 50%

c) 15%

d) 30%

Clear selection

12. How to manage Mucormycosis

1 point

a) Control diabetes and diabetic ketoacidosis

b) Reduce steroids (if patient is still on) with aim to discontinue rapidly

c) Discontinue immunomodulating drugs

d) No antifungal prophylaxis needed

e) All the above

Clear selection

13.Clinical presentation of Cytokine Storm include

1 point

a) Dyspnea, ARDS

b) Renal failure

c) Coagulopathy

d) All of the above

Clear selection

14. Risk factors for severe Covid-19 does not include:

1 point

a) Older Age

b) Type-2-DM

c) Children

d) Patients with Cardiovascular disease

Clear selection

15. Hall mark of Moderate disease is:

1 point

a) Lung infiltrates (≥ 50% of lung field involved)

b) Blood oxygen saturation of 90%- 93%

c) Tachypnoea (RR > 30 breaths per minute)

d) Ratio of Partial pressure of arterial oxygen to fraction of inspired oxygen 300

Clear selection

16. SARS Cov-2 replication is greatest during:

1 point

a) Just before onset of symptoms

b) In the 2nd week of disease

c) Soon after onset of symptoms

d) During convalescence

e) Both A and C

Clear selection

17. Not a criteria for ED evaluation and hospital admission

1 point

a) Severe dyspnoea

b) Oxygen saturation on room air of 94 %

c) Confusion, change in behavior

d) Chest pain

Clear selection

18. Outline of treatment in an admitted patient with moderate disease includes:

1 point

a)oxygen support

b)Immunomodulatory therapy

c)Anticoagulation

d)Monitoring of physical and laboratory parameters

e)all of the above

Clear selection

19. Remdesivir should not be considered in patients with:

1 point

a)Moderate disease requiring supplemental oxygen

b)Patients with no renal or hepatic dysfunction and with severe disease

c)Patients with mild disease who are not on oxygen support

d)Patients who are within 10 days of onset of symptoms with moderate disease.

Clear selection

20. Toclizumab may not be considered when:

1 point

a)Presence of severe disease

b)Significantly raised inflammatory markers

c)Active bacterial/fungal/tubercular infection

d)Not improving despite use of steroids

Clear selection

Submit

Clear form

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

Forms